Presenter's Information

David Joel Cohen, MD

Country USA
Specialty Interventional Cardiologist
  1. Innovation in TAVR: What Can We Expect for the Next Decade?
  2. Quality of Life Benefits of Tricuspid Valve Therapies - Insights From the TRILUMINATE Trial
  3. Challenges With Valve-in-Valve TAVR - Role of Bioprosthetic Valve Fracture, Coronary Protection, and Leaflet Modification
  4. PARTNER 3 Low Risk 5 Year Clinical and Echocardiographic Follow-up
  5. Novel Drug-Eluting Stent Designs: Not Yet Plateau, Still Need to Go!!!
  6. Contemporary Best Antiplatelet Strategy in HBR or CHIP Patients: How and What?
  7. Cost-Effectiveness of TEER - Insights From the COAPT Trial
  8. Challenges with ViV TAVR - Role of Bioprosthetic Valve Fracture, Coronary Protection, and Leaflet Modification
  9. Temporal Trends in TAVR Indication and Outcomes - Insights from the US TVT Registry
  10. Optimal Indication for CEP for TAVR: Insights from the STS-TVR and PROTECTED-TAVR
  11. Year-In-Review: Transcatheter Valve Therapy
  12. How Recent Guidelines Will Change the Approach of Mitral Disease Management in the Coming Years
  13. Left Main Revascularization; Consensus and Gaps in 2023
  14. Cost-effectiveness of TMVR (MitraClip)- Insights from the COAPT Trial
  15. Optimal Indication for Cerebral Embolic Protection for TAVR: Insights from the TVT Registry
  16. TAVR Economics and Efficiencies: Insights from the First Decade
  17. Economic Outcomes of TAVR vs SAVR for Low-Risk Patients: Results from the PARTNER 3 Trial
  18. Bioprosthetic Valve Fracture for Optimization of Valve-in-Valve: When, Why, and How?
  19. Composite Outcomes and Net Adverse Events: Implications for Trial Design and Interpretation
  20. COVID-19 and RAAS Inhibitors
  21. Who Should Not Undergo TAVR? Key Insights from the Pivotal Trials and Registries
  22. Quality of Life Outcomes of Transcatheter Mitral Valve Repair: Insights from the COAPT
  23. QOL Outcomes of the COAPT Trial
  24. A Journey of PCSK9 Inhibitors: From Genetics To Clinics
  25. The Emerging Role of NOACs in the Management of Stable CAD and PAD
  26. Failing Bioprosthetic Valves: Valve Fracture, Basilica, and Others
  27. ViV TAVR: The Role of Bioprosthetic Valve Fracture
  28. Valve-in-Valve: TAVR with BVF(Bioprosthetic Valve Fracture): In-Depth Techniques and Updated Data
  29. TAVR: Insights from Quality of Life and Economic Evaluation
  30. Stable CAD & PAD: COMPASS Trial - Will It Change Practice?
  31. PARTNER 2A and SAPIEN 3 Cost-Effectiveness: Cost-effectiveness of TAVR Versus SAVR in Intermediate Risk Patients with Aortic Stenosis
  32. Expanding Role of NOAC in PCI/AF, ACS, and Stable ASCVD: Recent Trials and Next Expectations
  33. Bioprosthetic Valve Fracture for Optimizing the Results of Valve in Valve TAVR
  34. TAVR: Insights from QOL and Economic Evaluation
  35. Selecting the Appropriate Patients for Long-term DAPT; Insights from PEGASUS TIMI-54
  36. ACS and DAPT Duration: Which One and How Long?
  37. TAVR - Year in Review
  38. Finding from PARTNER II Quality of Life Data
  39. What Is the Optimal Duration of DAPT After PCI/DES?
  40. Bioresorbable Vascular Scaffolds and DAPT Duration: The Longer the Better?
  41. Selecting the Appropriate Patients for Long-Term DAPT; Insights from Latest Trials
  42. Extremely High Risk for TAVR - Insights from QOL and Cost-Effectiveness Studies
  43. Optimizing Antiplatelet Therapy: Balancing Ischemic & Bleeding Risks
  44. Pretreatment with P2Y12 Inhibitors: When Selective vs. Routine Is Used?
  45. Cost-Effectiveness and Its Clinical Application
  46. Cost-Effectiveness of PCI for LM Disease
  47. Six Months Enough!
  48. Quality of Life After TAVI: What Do We Know? Why Should You Care?
  49. Guideline Today: Preload Prior to PCI - Standard of Care
  50. Early Insights on Cost-effectiveness
  51. CABG Status 2013: (i) Is Off-pump a Real Option? (ii) Aftermath of FREEDOM Results
  52. Counterpoint: Resisting the Bioabsorbable DES "Bandwagon": A Healthy Dose of Skepticism
  53. Why the Adoption of New Agents Is So Low?
  54. Management Guideline for Ischemic HF
  55. When Is TAVI Not Cost-effective?
  56. How to Overcome the Challenges?: New Agents - Prasugrel
  57. Nuances of Clinical Trials: Trial Size, Power Analysis, Sub Groups
  58. New Thienopyridine Use in ACS and PCI (TRITON-TIMI 38 and Several Subgroup Analyses, PLATO and Several Subgroup Analyses, and CHAMPION Trials)
  59. Cost-Effectiveness of Prasugrel vs. Clopidogrel in ACS
  60. Optimal Dosing of Antiplatelet Therapy in Patients With ACS Undergoing an Early Invasive Strategy: Insight from CURRENT-OASIS7 Trial
  61. Clopidogrel: Current OASIS7 - Double Is Better !!
  62. The Nuances of Superiority and Non-Inferiority Trials: Design Considerations, Choice of Endpoints, Cost Effectiveness Analyses
  63. Randomized Trials vs. Observational Registries: Strengths and Weaknesses
  64. Structural Heart Disease
  65. Updated Antiplatelet Therapy After PCI; Prasugrel, AZD6140..;The Future We Can Expect in Routine Practice?
Conference Slides
Category